reports
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sust...
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgrou...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company’s common stock with an exercise price of $12.49, the closing trading price of the Company’s common stock on the Nasd...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtu...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the C...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Major Low Likely in Place on S&P 500 In our 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. We also said it likely means at least another 2-4 weeks of consolidation, that one or two 8-10% pullbacks in a given year on the SPX is common (even during bull markets), and to not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers...
WRN WESTERN COPPER AND GOLD
TSLA TESLA INC
TMO THERMO FISHER SCIENTIFIC INC.
SCCO SOUTHERN COPPER CORPORATION
ORI OLD REPUBLIC INTERNATIONAL CORPORATION
MSTR MICROSTRATEGY INCORPORATED CLASS A
KMPR KEMPER CORPORATION
HMN HORACE MANN EDUCATORS CORPORATION
FCX FREEPORT-MCMORAN INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
TKO. TASEKO MINES LIMITED
AIG AMERICAN INTERNATIONAL GROUP INC.
K. KINROSS GOLD CORPORATION
AIZ ASSURANT INC.
19KQ BALWIN PROPERTIES PTY LTD
THG HANOVER INSURANCE GROUP INC.
WRB W. R. BERKLEY CORPORATION
PLTR PALANTIR TECHNOLOGIES
Coty Divests Stake in SKKN by Kim
NEW YORK--(BUSINESS WIRE)-- Coty Inc. (Coty Inc. (NYSE: COTY) (Paris: COTY) ("Coty" or "the Company") today announced the conclusion of its partnership with Kim Kardashian and the SKKN by Kim (“SKKN”) brand, with the closing of the sale of its 20% stake in the brand to SKIMS. Following the transaction, SKIMS will be uniting the beauty and lifestyle ventures under one brand. Anna von Bayern, CEO of Kylie Cosmetics and leader of Kim Kardashian’s beauty business at Coty, says: “Since Coty’s establishment over 120 years ago, we have remained at the forefront of consumer innovation. We are the go-...
Coty organise un panel d'experts pour déconstruire les mythes de la be...
NEW YORK--(BUSINESS WIRE)-- Coty (NYSE : COTY) (Paris : COTY), l’une des plus grandes entreprises de beauté au monde, possédant un portefeuille emblématique de marques dans les domaines du parfum, du maquillage, du soin de la peau et du corps, a organisé une afin de discuter des définitions restrictives de la beauté. Dans le cadre du nouveau chapitre de la campagne primée #UndefineBeauty, le panel déconstruit les mythes liés à la beauté et intègre des perspectives issues des neurosciences, de l’art, des réseaux sociaux, de la sociologie et de la santé mentale, mettant en avant la nécessité d’...
Coty Hosts Expert Panel to Bust Beauty Myths and #UndefineBeauty
NEW YORK--(BUSINESS WIRE)-- Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies, with an iconic portfolio of brands across fragrance, color cosmetics, skin and body care, hosted a to discuss restrictive beauty ideals and definitions. As the next chapter of the award-winning #UndefineBeauty campaign, the panel debunks beauty myths and includes perspectives on neuroscience, art, social media, sociology, and mental health, and underscores the need for collective action to drive change. This press release features multimedia. View the full release here: Coty #UndefineBeau...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Pr...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout in 2H25 Company expects to initiate Phase 2 pediatric basket trial of Decartes-08 in select autoimmune indications in 2H25 Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $214.3...
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company’s common stock with an exercise price of $17.50, the closing trading price of the Company’s common stock on the Nasdaq Global Mar...
Coty Provides Update on Category Leadership, Financial Progress, and S...
NEW YORK--(BUSINESS WIRE)-- Regulatory News: Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care, is pleased to confirm that Chief Executive Officer Sue Nabi and Chief Financial Officer Laurent Mercier will present at the 2025 Consumer Analyst Group of New York Conference (CAGNY) on Wednesday, February 19 at 4:00pm EST or 10:00pm CET. Coty will provide an update on its category leadership, financial and strategic progress, and how it plans to fuel outperformance of the beauty ...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March: A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference at 1:00 p.m. ET on Tuesday, February 25, 2025A presentation at the TD Cowen 45th Annual Health Care Conference...
Moody's Ratings upgrades Coty's CFR to Ba1; outlook stable
Moody's Ratings (Moody's) today upgraded Coty Inc.'s ("Coty") Corporate Family Rating ("CFR") to Ba1 from Ba2, its Probability of Default Rating to Ba1-PD from Ba2-PD, the company's senior secured first lien revolving credit facility rating to Ba1 from Ba2, the senior secured notes ratings to Ba1 fr...
Coty Reports Solid 1H25 Financial Performance, With Strong Margin Expa...
NEW YORK--(BUSINESS WIRE)-- Regulatory News: Coty Inc. (NYSE: COTY) (Paris: COTY) ("Coty" or "the Company") today announced its results for the first half and second quarter of fiscal year 2025, ended December 31, 2024. Across both periods, the Company delivered strong gross and operating margin expansion, while continuing to invest behind its brands and execute across its strategic growth pillars. In 1H25, Coty's reported net revenue decreased 1% year-over-year and included a 2% negative impact from FX and a 1% headwind from the divestiture of the Lacoste license. Coty's LFL net revenue g...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On February 3, 2025, the Company issued to these employees options to purchase an aggregate of 168,360 shares of the Company’s common stock with an exercise price of $19.89, the closing trading price of the Company’s common stock on ...
Citizens Community Bancorp, Inc. Reports Fourth Quarter 2024 Earnings ...
Citizens Community Bancorp, Inc. Reports Fourth Quarter 2024 Earnings of $0.27 Per Share and Twelve Month 2024 Earnings of $1.34 Per Share; Board of Directors Increases Annual Dividend by 12.5% to $0.36 Per Share EAU CLAIRE, Wis., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Citizens Community Bancorp, Inc. (the “Company”) (Nasdaq: CZWI), the parent company of Citizens Community Federal N.A. (the “Bank” or “CCFBank”), today reported earnings of $2.7 million and earnings per diluted share of $0.27 for the fourth quarter ended December 31, 2024, compared to $3.3 million and earnings per diluted share ...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agree...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis Trial on track to commence in 1H25 FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Prioriti...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient administration based on updated data shared in December 2024 Phase 2 systemic lupus erythematosus (SLE) trial of Descartes-08 ongoing with expected data readout in 2H25 Cash resources expected to support pla...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.